Please login to the form below

Not currently logged in

New oral contraceptive launched in Europe

Bayer Schering Pharma has begun the rollout of its new oral contraceptive Qlaira in several European countries

Bayer Schering Pharma has begun the rollout of its new oral contraceptive Qlaira (estradiol valerate/dienogest) in several European countries, with more to follow from autumn 2009.

Qlaira is the first of a new class of oral contraceptives, delivering a form of oestrogen (estradiol) identical to that produced by the female reproductive system. Oral contraceptives available to women up until now have contained the oestrogen component ethinylestradiol.

Qlaira uses a unique dosing regimen to combine the oestrogen element of the pill with the progestin in such a way to deliver the correct levels of hormones at the right time in a woman's monthly cycle, resulting in reliable contraception and good cycle control.

"We are highly delighted that we will now bring Qlaira – our latest innovation in the field of contraception – to women all over Europe," said Dr Phil Smits, head of Women's Healthcare at Bayer Schering Pharma.

The company is also looking to gain approval for the additional indication for the treatment of prolonged heavy and frequent bleeding in women who wish to use oral contraception. No other contraception is currently approved for treating this condition.

14th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...